Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun 15;201(12):1579-1580.
doi: 10.1164/rccm.202002-0359LE.

Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Kelly E Dooley  1 , Sachiko Miyahara  2 , Florian von Groote-Bidlingmaier  3   4 , Xin Sun  2 , Richard Hafner  5 , Susan L Rosenkranz  2   6 , Elisa H Ignatius  1 , Eric L Nuermberger  1 , Laura Moran  7 , Kathleen Donahue  6 , Susan Swindells  8 , Naadira Vanker  3   4 , Andreas H Diacon  3   4
Affiliations
Comment

Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Kelly E Dooley et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, et al. A5312 Study Team. Early bactericidal activity of different isoniazid doses for drug resistant TB (INHindsight): a randomized open-label clinical trial. Am J Respir Crit Care Med. [online ahead of print] 16 Jan 2020; DOI: 10.1164/rccm.201910-1960OC. - PMC - PubMed
    1. Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet. 2019;58:1103–1129. - PubMed
    1. Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15:e1002591. - PMC - PubMed
    1. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684–692. - PubMed
    1. Walsh KF, Vilbrun SC, Souroutzidis A, Delva S, Joissaint G, Mathurin L, et al. Improved outcomes with high-dose isoniazid in multidrug-resistant tuberculosis treatment in Haiti. Clin Infect Dis. 2019;69:717–719. - PMC - PubMed